Celularity Inc. CELU
0.47 USD -0.02 (-3.15%)
Regular-session close
0.46 -0.01 -1.54%
After hours · Nov 19, 4:00 PM ET
0.4604 Day range 0.5216
0.4604 52-week range 2.55
- YTD
- -57.85%
- 1 year
- -72.31%
News
newsfilecorp.com Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development Appointment Follows US$6.5 Million Strategic Financing and Strengthens Board Leadership Alongside David Adelman, Kevin Mayer, Lee Applbaum and James McRoberts Vancouver, British Columbia and…
defenseworld.net Celularity (NASDAQ:CELU) and Onconetix (NASDAQ:ONCO) Financial Contrast Onconetix (NASDAQ: ONCO - Get Free Report) and Celularity (NASDAQ: CELU - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies…benzinga.com Celularity Enters Manufacturing Agreement With Vesalius For Its Peptual-Branded Peptide Active Pharmaceutical Ingredients Deal to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients ("APIs").The collaboration…
businesswire.com Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States FLORHAM PARK, N.J. & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs…benzinga.com Celularity Regains Nasdaq Compliance Celularity Inc. (Nasdaq: CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications…
globenewswire.com Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received…
globenewswire.com Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
globenewswire.com Celularity Announces Naveen Jain to Join Board of Directors FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and…
globenewswire.com Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1 2027.
gurufocus.com Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform [url="]Celularity Inc.[/url] (Nasdaq: CELU) (âCelularityâ), a longevity-focused regenerative and cellular medicine company, and [url="]MuseCell InnovationsÂ
businesswire.com Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform FLORHAM PARK, N.J. & SINGAPORE--(BUSINESS WIRE)--Celularity Inc. and MuseCell Innovations announce U.S. manufacturing partnership for production of Dezawa MuseCells in Florham Park, NJ facility.
globenewswire.com Celularity Provides Update Regarding Nasdaq Listing Compliance FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing…
globenewswire.com Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies FLORHAM PARK, N.J. and ORLANDO, Fla.
globenewswire.com Celularity Releases CEO Letter to Shareholders FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering…
globenewswire.com Celularity Appoints Rick Gonzalez as Chief Commercial Officer FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering…
globenewswire.com Celularity Receives Nasdaq Notice Regarding Form 10-Q FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a…
globenewswire.com Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation Company advances focused strategy, strengthens balance sheet and positions business for long-term growth Company advances focused strategy, strengthens balance sheet and positions business for…
globenewswire.com NEXGEL Appoints Ian Blackman as Chief Financial Officer Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL”…
globenewswire.com NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified…
globenewswire.com Celularity Announces Closing of Transaction with NexGel FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of…
globenewswire.com Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April…
defenseworld.net KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses…
